Showing results (1261-1270 of 1,299) with videos related to

Sort By:
Pageof 130
BMC Medicine|March 7, 2023
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCCYong Li, Aiping Zhou, Shuoyan Liu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 14, 2024
An optimized short-term steroid therapy for chronic drug-induced liver injury: A prospective randomized clinical trialAng Huang, Yun Zhu, Shuhong Liu, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 25, 2023
Late-Onset Anti-GABA<sub>B</sub> Receptor Encephalitis: Clinical Characteristics and Outcomes Differing From Early-Onset PatientsTangna Sun, Daidi Zhao, Gejuan Zhang, et al.
ACS Nano|August 22, 2025
2 × 2 Charge Density Wave in Fe<sub>0.33</sub>NbSe<sub>2</sub> Stabilized by Disordered IntercalationHui Tian, Tongrui Li, Yunmei Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|September 5, 2021
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitorsYufang Xiao, Bayard R Huck, Ruoxi Lan, et al.
JMIR Cancer|February 11, 2025
Interpretable Machine Learning to Predict the Malignancy Risk of Follicular Thyroid Neoplasms in Extremely Unbalanced Data: Retrospective Cohort Study and Literature ReviewRui Shan, Xin Li, Jing Chen, et al.
The Lancet. Diabetes & Endocrinology|May 3, 2016
BMI, leisure-time physical activity, and physical fitness in adults in China: results from a series of national surveys, 2000-14Ye Tian, Chongmin Jiang, Mei Wang, et al.
Journal of Medicinal Chemistry|October 1, 2021
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered CancersLizbeth DeSelm, Bayard Huck, Ruoxi Lan, et al.
Alimentary Pharmacology & Therapeutics|April 1, 2022
Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trialJia-Bo Wang, Ang Huang, Yijin Wang, et al.
Nature Communications|February 28, 2023
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variantsJames Logue, Robert M Johnson, Nita Patel, et al.
Pageof 130